-
METHODOLOGICAL REVIEW OF CAPACITY CONSTRAINT MODELING IN SIMULATIONS INFORMING ORGAN TRANSPLANTATION
Aug 11, 2026, 17:16 PM -
HEALTHCARE COSTS AND ECONOMIC BURDEN OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA) AND RELATED MOTOR NEURON DIAGNOSES IN TURKIYE: A REAL-WORLD DATA ANALYSIS
Aug 11, 2026, 17:16 PM -
EVALUATING THE IMPACT OF FRANCE'S DEROGATORY DIRECT ACCESS SCHEME:INSIGHTS FROM THE PUBLIC HOSPITALS OF PARIS (AP-HP) FRAMEWORK
Aug 11, 2026, 17:16 PM -
EVALUATION OF EVIDENCE SOURCE AND ANALYSES TYPE PRESENTED IN RARE DISEASE NICE SUBMISSIONS AS INCLUSION IN JCA APPROACHES
Aug 11, 2026, 17:16 PM -
GREECE'S STRUCTURAL CO-PAYMENT BURDEN OF PATIENTS WITH MULTIMORBIDITY—A 13-COUNTRY EUROPEAN COMPARISON
Aug 11, 2026, 17:16 PM -
UNCERTAINITY IN PIVOTAL CLINICAL TRIALS AND REGULATORY OUTCOME IN EUROPE
Aug 11, 2026, 17:16 PM -
WHEN EVIDENCE IS NON-RANDOMIZED: HTA DECISIONS IN ATMPS ASSESSMENTS. A CROSS-AGENCY TARGETED REVIEW
Aug 11, 2026, 17:16 PM -
A SOCIAL MEDIA LISTENING ANALYSIS OF PERCEIVED HEALTH IMPROVEMENTS ASSOCIATED WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) USE BEYOND WEIGHT-LOSS AND DIABETES-FOCUSED COMMUNITIES
Aug 11, 2026, 17:16 PM -
MOST FAVOURED NATION DRUG PRICING IN THE US: WHY A NATIONAL HTA AGENCY IS NEEDED BEYOND INTERNATIONAL REFERENCE PRICING
Aug 11, 2026, 17:16 PM -
DISEASE BURDEN AND HEALTHCARE UTILIZATION AFTER DIAGNOSIS OF NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS (NF1-PN) IN SWEDISH ADULT PATIENTS: A REGISTRY-BASED STUDY
Aug 11, 2026, 17:16 PM -
PAYER PERSPECTIVES ON THE POTENTIAL IMPACT OF US MOST-FAVOURED-NATION POLICIES ON PHARMACEUTICAL PRICING AND ACCESS: FINDINGS FROM A MULTI-COUNTRY QUALITATIVE ASSESSMENT
Aug 11, 2026, 17:16 PM -
REGIONAL VARIATION IN PRESCRIPTION DRUG USE IN PUBLIC REIMBURSEMENT CLAIMS IN JAPAN: AN ANALYSIS OF NDB OPEN DATA
Aug 11, 2026, 17:16 PM -
FIFTEEN YEARS OF GERMAN HTA (AMNOG): TRENDS AND DRIVERS OF "NO ADDED BENEFIT"
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG INTRAVENOUS IRON USERS: A REAL-WORLD COMPARISON BETWEEN PATIENTS WITH AND WITHOUT CONCOMITANT HEMOTHERAPY IN A BRAZILIAN HEALTH PLAN
Aug 11, 2026, 17:16 PM -
ANTIBIOTIC EXPENDITURE AMONG HOSPITALIZED PATIENTS USING THE WORLD HEALTH ORGANIZATION AWARE CLASSIFICATION IN TUNISIA
Aug 11, 2026, 17:16 PM -
SURROGATE ENDPOINTS, CLINICAL UNCERTAINTY, AND REAL-WORLD DECISION-MAKING: LESSONS FROM HB-HTA OF TOFERSEN IN AMYOTROPHIC LATERAL SCLEROSIS
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION OF SCREENING FOR PRIMARY ALDOSTERONISM IN PATIENTS WITH HYPERTENSION ACROSS MULTIPLE COUNTRIES
Aug 11, 2026, 17:16 PM -
FORECASTING UK BRANDED MEDICINES SPEND UNDER VPAG: A MACHINE-LEARNING MODEL INTEGRATING NHS PRESCRIBING AND COMMERCIAL SALES DATA
Aug 11, 2026, 17:16 PM -
BRIDGING EUROPEAN AND NATIONAL HTA: IMPLEMENTATION OF JOINT CLINICAL ASSESSMENTS ACROSS EU MEMBER STATES
Aug 11, 2026, 17:16 PM -
EXPLORING THE FUTURE TREATMENT LANDSCAPE OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): HOW CLINICAL TRIAL LINE OF THERAPY (LOT) ELIGIBILITY MAY RESHAPE TREATMENT SEQUENCING
Aug 11, 2026, 17:16 PM
